Salicylamide

Identification

Name
Salicylamide
Accession Number
DB08797
Type
Small Molecule
Groups
Approved
Description

Salicylamide is the common name for the substance o-hydroxybenzamide, or amide of salicyl. Salicylamide is a non-prescription drug with analgesic and antipyretic properties. Its medicinal uses are similar to those of aspirin. Salicylamide is used in combination with both aspirin and caffeine in the over-the-counter pain remedies

Structure
Thumb
Synonyms
  • 2-Carbamoylphenol
  • 2-Carboxamidophenol
  • 2-Hydroxybenzamide
  • o-hydroxybenzamide
  • OHB
  • Salicilamida
  • Salicylamidum
  • Salicylic acid amide
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
ExaprinSalicylamide (152 mg/1) + Acetaminophen (110 mg/1) + Acetylsalicylic acid (162 mg/1) + Caffeine (32.4 mg/1)TabletOralHART Health1987-01-20Not applicableUs
Extra Strength Pain RelieverSalicylamide (152 mg/1) + Acetaminophen (110 mg/1) + Acetylsalicylic acid (162 mg/1) + Caffeine (32.4 mg/1)TabletOralRedicare Llc2017-10-01Not applicableUs
Green Guard Pain and Ache ReliefSalicylamide (152 mg/1) + Acetaminophen (110 mg/1) + Acetylsalicylic acid (162 mg/1) + Caffeine (32.4 mg/1)TabletOralUnifirst First Aid2008-12-30Not applicableUs
Medi First Pain ReliefSalicylamide (152 mg/1) + Acetaminophen (110 mg/1) + Acetylsalicylic acid (162 mg/1) + Caffeine (32.4 mg/1)TabletOralUnifirst First Aid2008-12-30Not applicableUs
Medi First Plus Pain ZapperSalicylamide (152 mg/1) + Acetaminophen (110 mg/1) + Acetylsalicylic acid (162 mg/1) + Caffeine (32.4 mg/1)TabletOralUnifirst First Aid2008-12-30Not applicableUs
Pain FreeSalicylamide (152 mg/1) + Acetaminophen (110 mg/1) + Acetylsalicylic acid (162 mg/1) + Caffeine (32.4 mg/1)TabletOralAfassco Inc.2016-10-25Not applicableUs
Pain RelieverSalicylamide (152 mg/1) + Acetaminophen (110 mg/1) + Acetylsalicylic acid (162 mg/1)TabletOralAdvanced First Aid, Inc.2015-04-07Not applicableUs
Pain Stopper ExtraSalicylamide (152 mg/1) + Acetaminophen (110 mg/1) + Acetylsalicylic acid (162 mg/1) + Caffeine (32.4 mg/1)TabletOralNorth Safety Products2012-03-072017-12-22Us
Pain StoppersSalicylamide (152 mg/1) + Acetaminophen (110 mg/1) + Acetylsalicylic acid (162 mg/1) + Caffeine (32.4 mg/1)TabletOralNorth Safety Products2017-01-02Not applicableUs
Pain Stoppers RegularSalicylamide (152 mg/1) + Acetaminophen (110 mg/1) + Acetylsalicylic acid (162 mg/1) + Caffeine (32.4 mg/1)TabletOralNorth Safety Products2013-04-182017-12-22Us
Categories
UNII
EM8BM710ZC
CAS number
65-45-2
Weight
Average: 137.136
Monoisotopic: 137.047678473
Chemical Formula
C7H7NO2
InChI Key
SKZKKFZAGNVIMN-UHFFFAOYSA-N
InChI
InChI=1S/C7H7NO2/c8-7(10)5-3-1-2-4-6(5)9/h1-4,9H,(H2,8,10)
IUPAC Name
2-hydroxybenzamide
SMILES
NC(=O)C1=CC=CC=C1O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Oral, rat LD50: 1890 mg/kg

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Salicylamide is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Salicylamide is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Salicylamide is combined with 5-androstenedione.Experimental, Illicit
AbciximabSalicylamide may increase the anticoagulant activities of Abciximab.Approved
AcebutololSalicylamide may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Salicylamide.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Salicylamide is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolSalicylamide may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Salicylamide.Approved, Vet Approved
AclarubicinSalicylamide may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Salicylamide.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Salicylamide is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Aldosterone.Experimental, Investigational
AldoxorubicinSalicylamide may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level.Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Salicylamide is combined with Alendronic acid.Approved
AliskirenSalicylamide may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Salicylamide is combined with Alminoprofen.Experimental
AlprenololSalicylamide may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Salicylamide.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Amcinonide.Approved
AmikacinSalicylamide may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideSalicylamide may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinSalicylamide may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodSalicylamide may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Salicylamide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Salicylamide is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Salicylamide is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Salicylamide is combined with Anisodamine.Investigational
AnnamycinSalicylamide may decrease the excretion rate of Annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Salicylamide.Approved
Antithrombin III humanSalicylamide may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanSalicylamide may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Salicylamide is combined with Apocynin.Investigational
ApramycinSalicylamide may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Salicylamide.Approved, Investigational
ArbekacinSalicylamide may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinSalicylamide may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanSalicylamide may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololSalicylamide may decrease the antihypertensive activities of Arotinolol.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Atamestane.Investigational
AtenololSalicylamide may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Salicylamide.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Salicylamide.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Salicylamide.Approved
BalsalazideSalicylamide may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminSalicylamide may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololSalicylamide may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinSalicylamide may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Salicylamide.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Salicylamide is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Salicylamide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Salicylamide.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Salicylamide is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Salicylamide.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Betamethasone.Approved, Vet Approved
BetaxololSalicylamide may decrease the antihypertensive activities of Betaxolol.Approved
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Salicylamide.Approved, Investigational
BevantololSalicylamide may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Salicylamide is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Salicylamide.Approved, Investigational
BisoprololSalicylamide may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinSalicylamide may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololSalicylamide may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Salicylamide.Approved
BucillamineThe risk or severity of adverse effects can be increased when Salicylamide is combined with Bucillamine.Investigational
BucindololSalicylamide may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Salicylamide is combined with Bufexamac.Experimental
BufuralolSalicylamide may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Bumadizone.Experimental
BumetanideSalicylamide may decrease the diuretic activities of Bumetanide.Approved
BupranololSalicylamide may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Salicylamide.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Salicylamide.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Salicylamide.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Salicylamide.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Salicylamide is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Salicylamide.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Salicylamide.Approved, Vet Approved, Withdrawn
CarteololSalicylamide may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolSalicylamide may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Salicylamide.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Salicylamide.Approved, Investigational
CeliprololSalicylamide may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinSalicylamide may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Salicylamide.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Salicylamide.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Salicylamide.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Salicylamide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Salicylamide.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Salicylamide.Approved
CinoxacinSalicylamide may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Citric AcidSalicylamide may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Salicylamide is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Salicylamide is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Salicylamide is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Salicylamide.Vet Approved
CloranololSalicylamide may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Salicylamide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Salicylamide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Salicylamide is combined with Curcumin.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Salicylamide.Experimental
CyclosporineSalicylamide may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateSalicylamide may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinSalicylamide may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidSalicylamide may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanSalicylamide may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinSalicylamide may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Salicylamide is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Salicylamide is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Salicylamide.Experimental
DesirudinSalicylamide may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Salicylamide is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Salicylamide.Approved, Investigational
DextranSalicylamide may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Salicylamide may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Salicylamide may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Salicylamide may increase the anticoagulant activities of Dextran 75.Approved
DibekacinSalicylamide may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Salicylamide.Approved, Vet Approved
DicoumarolSalicylamide may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Salicylamide.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Salicylamide.Approved
DihydrostreptomycinSalicylamide may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Salicylamide.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Salicylamide.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Salicylamide.Approved
DoxorubicinSalicylamide may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneSalicylamide may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Salicylamide is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Salicylamide is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Salicylamide is combined with E-6201.Investigational
Edetic AcidSalicylamide may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanSalicylamide may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Salicylamide.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Salicylamide.Approved
EnoxacinSalicylamide may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinSalicylamide may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Salicylamide.Experimental
EpanololSalicylamide may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Salicylamide is combined with Epirizole.Approved
EpirubicinSalicylamide may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneSalicylamide may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Salicylamide.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Salicylamide.Approved
EquileninThe risk or severity of adverse effects can be increased when Salicylamide is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Salicylamide is combined with Equilin.Approved
EsmololSalicylamide may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Estrone sulfate.Approved
Etacrynic acidSalicylamide may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Salicylamide.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Ethenzamide.Experimental
Ethyl biscoumacetateSalicylamide may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Salicylamide is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Salicylamide.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Salicylamide.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Salicylamide is combined with Evening primrose oil.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Salicylamide.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Salicylamide.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Salicylamide is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Salicylamide.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Salicylamide.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Salicylamide is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Feprazone.Experimental
Ferulic acidSalicylamide may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Salicylamide.Approved, Investigational
FleroxacinSalicylamide may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Salicylamide.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Fludrocortisone.Approved
FluindioneSalicylamide may increase the anticoagulant activities of Fluindione.Investigational
FlumequineSalicylamide may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Salicylamide is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Salicylamide is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Salicylamide.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Salicylamide.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Salicylamide.Approved, Nutraceutical, Vet Approved
FondaparinuxSalicylamide may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumSalicylamide may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Salicylamide.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Salicylamide.Approved
FramycetinSalicylamide may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideSalicylamide may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateSalicylamide may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinSalicylamide may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinSalicylamide may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Salicylamide.Approved, Withdrawn
GemifloxacinSalicylamide may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinSalicylamide may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinSalicylamide may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ASalicylamide may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150Salicylamide may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinSalicylamide may increase the neuroexcitatory activities of Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Salicylamide is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Salicylamide is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Salicylamide is combined with HE3286.Investigational
HeparinSalicylamide may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Salicylamide is combined with Higenamine.Investigational
HydralazineSalicylamide may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Salicylamide.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Salicylamide.Approved, Investigational
Hygromycin BSalicylamide may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Salicylamide.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Salicylamide is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Salicylamide.Approved
IdarubicinSalicylamide may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxSalicylamide may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Salicylamide.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Salicylamide.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Salicylamide.Approved
IndenololSalicylamide may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Salicylamide is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Salicylamide.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Salicylamide is combined with Indoprofen.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Salicylamide.Approved, Investigational
IsepamicinSalicylamide may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Salicylamide is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Salicylamide is combined with Istaroxime.Investigational
KanamycinSalicylamide may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Salicylamide.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Salicylamide.Approved
LabetalolSalicylamide may decrease the antihypertensive activities of Labetalol.Approved
LandiololSalicylamide may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Salicylamide.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Salicylamide.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Salicylamide.Approved, Investigational
LepirudinSalicylamide may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanSalicylamide may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololSalicylamide may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinSalicylamide may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Salicylamide.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Salicylamide.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Salicylamide is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Salicylamide.Approved
LonazolacThe risk or severity of adverse effects can be increased when Salicylamide is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Salicylamide.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Salicylamide.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Salicylamide is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Salicylamide is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Salicylamide.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Salicylamide.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Salicylamide.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Salicylamide.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Salicylamide.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Salicylamide is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Salicylamide.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Salicylamide.Approved
MelagatranSalicylamide may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Salicylamide is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Salicylamide.Approved, Vet Approved
MepindololSalicylamide may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineSalicylamide may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Salicylamide.Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Salicylamide.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Salicylamide.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Methylprednisolone.Approved, Vet Approved
MetipranololSalicylamide may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Salicylamide.Approved
MetoprololSalicylamide may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideSalicylamide may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinSalicylamide may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Salicylamide.Approved
MizoribineThe risk or severity of adverse effects can be increased when Salicylamide is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Salicylamide.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Salicylamide.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Salicylamide.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Salicylamide.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Salicylamide.Approved
NadololSalicylamide may decrease the antihypertensive activities of Nadolol.Approved
NadroparinSalicylamide may increase the anticoagulant activities of Nadroparin.Approved
NafamostatSalicylamide may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Salicylamide.Approved
Nalidixic AcidSalicylamide may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Salicylamide.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Salicylamide is combined with NCX 1022.Investigational
NeamineSalicylamide may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololSalicylamide may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinSalicylamide may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinSalicylamide may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Salicylamide.Approved
NetilmicinSalicylamide may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Salicylamide.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Salicylamide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Salicylamide is combined with Nitroaspirin.Investigational
NorfloxacinSalicylamide may increase the neuroexcitatory activities of Norfloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Salicylamide.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Salicylamide.Approved
OlsalazineSalicylamide may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of can be d when Salicylamide is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Salicylamide.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Salicylamide is combined with Orgotein.Vet Approved
OtamixabanSalicylamide may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Salicylamide.Approved
Oxolinic acidSalicylamide may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololSalicylamide may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Salicylamide.Approved, Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Salicylamide.Approved
ParomomycinSalicylamide may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Parthenolide.Investigational
PazufloxacinSalicylamide may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinSalicylamide may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololSalicylamide may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateSalicylamide may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateSalicylamide may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Salicylamide.Approved
PhenindioneSalicylamide may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonSalicylamide may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Salicylamide.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Salicylamide.Approved, Investigational
PindololSalicylamide may decrease the antihypertensive activities of Pindolol.Approved
Pipemidic acidSalicylamide may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinSalicylamide may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideSalicylamide may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Salicylamide.Approved, Investigational
Piromidic acidSalicylamide may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Salicylamide.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Salicylamide is combined with Pirprofen.Experimental
Platelet Activating FactorSalicylamide may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinSalicylamide may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinSalicylamide may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Salicylamide.Approved
PractololSalicylamide may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Salicylamide.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Salicylamide is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Pregnenolone.Experimental, Investigational
ProbenecidThe serum concentration of Salicylamide can be increased when it is combined with Probenecid.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Salicylamide is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Salicylamide is combined with Propacetamol.Approved, Investigational
PropranololSalicylamide may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Salicylamide.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Salicylamide.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Salicylamide.Vet Approved
Protein CSalicylamide may increase the anticoagulant activities of Protein C.Approved
Protein S humanSalicylamide may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeSalicylamide may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinSalicylamide may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Salicylamide.Investigational
PuromycinSalicylamide may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Salicylamide.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Salicylamide.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Salicylamide.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Salicylamide.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Salicylamide.Approved, Experimental, Investigational
ReviparinSalicylamide may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinSalicylamide may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Risedronate.Approved, Investigational
RivaroxabanSalicylamide may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Salicylamide.Investigational, Withdrawn
RosoxacinSalicylamide may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinSalicylamide may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinSalicylamide may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Salicylamide.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Salicylamide.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Salicylamide.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Salicylamide.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Salicylamide.Approved
SemapimodThe risk or severity of adverse effects can be increased when Salicylamide is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Salicylamide.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Salicylamide is combined with Serrapeptase.Investigational
SisomicinSalicylamide may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinSalicylamide may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Salicylamide.Approved
SotalolSalicylamide may decrease the antihypertensive activities of Sotalol.Approved
SP1049CSalicylamide may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinSalicylamide may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinSalicylamide may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Salicylamide.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Salicylamide.Investigational
StreptomycinSalicylamide may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinSalicylamide may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Salicylamide.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Salicylamide.Approved
SulodexideSalicylamide may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Salicylamide.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Salicylamide.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Suxibuzone.Experimental
TacrolimusSalicylamide may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Salicylamide.Approved
TalinololSalicylamide may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Salicylamide.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Salicylamide.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Salicylamide.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Salicylamide.Approved, Investigational
TemafloxacinSalicylamide may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Salicylamide.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Salicylamide is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Salicylamide is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Salicylamide.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Salicylamide is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Teriflunomide.Approved
TertatololSalicylamide may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Salicylamide.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Salicylamide is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololSalicylamide may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Salicylamide is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Salicylamide is combined with Tixocortol.Approved, Withdrawn
TobramycinSalicylamide may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Salicylamide is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Salicylamide.Approved
TorasemideSalicylamide may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Salicylamide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Salicylamide.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Salicylamide.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Salicylamide.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Triamcinolone.Approved, Vet Approved
TriamtereneSalicylamide may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Salicylamide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Triptolide.Investigational
TrovafloxacinSalicylamide may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinSalicylamide may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Salicylamide is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Salicylamide.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Salicylamide.Investigational, Withdrawn
ValrubicinSalicylamide may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Salicylamide.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Salicylamide.Approved
WarfarinSalicylamide may increase the anticoagulant activities of Warfarin.Approved
XimelagatranSalicylamide may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Salicylamide.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Salicylamide.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Salicylamide.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Salicylamide is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Salicylamide.Withdrawn
Zoptarelin doxorubicinSalicylamide may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinSalicylamide may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

Synthesis Reference

Elijah J. Gold, Esther Babad, Lydia Peer, Wei K. Chang, "Preparation of (-)-5-(beta)-1-hydroxy-2-((beta)-1-methyl-3-phenylpropyl)aminoethyl) salicylamide." U.S. Patent US4658060, issued November, 1979.

US4658060
General References
Not Available
External Links
Human Metabolome Database
HMDB15687
PubChem Compound
5147
PubChem Substance
99445267
ChemSpider
4963
BindingDB
50056900
ChEBI
32114
ChEMBL
CHEMBL27577
HET
OHB
Wikipedia
Salicylamide
ATC Codes
N02BA75 — Salicylamide, combinations with psycholepticsN02BA05 — SalicylamideN02BA55 — Salicylamide, combinations excl. psycholeptics
PDB Entries
4k17
MSDS
Download (57 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)142 °CPhysProp
boiling point (°C)181.5 °CPhysProp
water solubility2060 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.28HANSCH,C ET AL. (1995)
pKa8.37 (at 20 °C)KORTUM,G ET AL (1961)
Predicted Properties
PropertyValueSource
Water Solubility7.82 mg/mLALOGPS
logP0.74ALOGPS
logP1.17ChemAxon
logS-1.2ALOGPS
pKa (Strongest Acidic)8.21ChemAxon
pKa (Strongest Basic)-1.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area63.32 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity37.12 m3·mol-1ChemAxon
Polarizability13.22 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9877
Blood Brain Barrier+0.9382
Caco-2 permeable+0.6048
P-glycoprotein substrateNon-substrate0.8565
P-glycoprotein inhibitor INon-inhibitor0.9817
P-glycoprotein inhibitor IINon-inhibitor0.9948
Renal organic cation transporterNon-inhibitor0.9178
CYP450 2C9 substrateNon-substrate0.8207
CYP450 2D6 substrateNon-substrate0.6203
CYP450 3A4 substrateNon-substrate0.7067
CYP450 1A2 substrateNon-inhibitor0.7061
CYP450 2C9 inhibitorNon-inhibitor0.952
CYP450 2D6 inhibitorNon-inhibitor0.9043
CYP450 2C19 inhibitorNon-inhibitor0.8779
CYP450 3A4 inhibitorNon-inhibitor0.8828
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9144
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.864
BiodegradationReady biodegradable0.7192
Rat acute toxicity2.1150 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9867
hERG inhibition (predictor II)Non-inhibitor0.9468
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-00du-4900000000-f5a22e5a4fb556796bd9
GC-MS Spectrum - EI-BGC-MSsplash10-00du-8900000000-701c75263149bd35390b
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , negativeLC-MS/MSsplash10-000i-1900000000-132217380eb9a2784eb0

Taxonomy

Description
This compound belongs to the class of organic compounds known as 1-hydroxy-4-unsubstituted benzenoids. These are phenols that are unsubstituted at the 4-position.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenols
Sub Class
1-hydroxy-4-unsubstituted benzenoids
Direct Parent
1-hydroxy-4-unsubstituted benzenoids
Alternative Parents
1-hydroxy-2-unsubstituted benzenoids / Benzene and substituted derivatives / Carboximidic acids / Organopnictogen compounds / Organooxygen compounds / Organonitrogen compounds / Hydrocarbon derivatives
Substituents
1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid / Monocyclic benzene moiety / Carboximidic acid derivative / Carboximidic acid / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Hydrocarbon derivative / Organooxygen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
phenols, salicylamides (CHEBI:32114) / a small molecule (SALICYLAMIDE)

Drug created on October 08, 2010 16:10 / Updated on November 09, 2017 04:40